Knopp Biosciences to Present Details of Positive Results From the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021
13.5.2021 13:00:00 EEST | Business Wire | Press release
Knopp Biosciences LLC today announced it will present detailed results of its positive Phase 2 dose-ranging EXHALE trial of the novel oral eosinophil-lowering drug dexpramipexole in patients with moderate-to-severe asthma in a virtual poster session at the ATS 2021 International Conference.
“We look forward to sharing comprehensive results of the EXHALE trial, which underscore the readiness of dexpramipexole for further development in eosinophilic asthma,” said Michael Bozik, M.D., president and CEO of Knopp. “Monoclonal antibody treatments approved for asthma demonstrate that reduction in eosinophils is associated with significantly improved outcomes, but the need remains for an oral alternative in the eosinophilic asthma treatment paradigm.”
Following are details of the poster presentation:
|
Poster Title |
Abstract Number / Presentation Details |
|
|
Oral Dexpramipexole Efficacy in Lowering Blood Eosinophils in Patients with Moderate to Severe Uncontrolled Eosinophilic Asthma
|
A1359 Poster Presentation
Presenter: Calman Prussin, M.D., VP, Clinical and Translational Medicine, Knopp Biosciences LLC
Time: 8 a.m. EDT
|
Follow Knopp Biosciences on Twitter via @KnoppBio and keep up to date with conference news and updates using the hashtag #ATS2021.
ABOUT KNOPP BIOSCIENCES LLC
Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases with high unmet need. Knopp’s clinical-stage oral small molecule, dexpramipexole, is in Phase 2 clinical trials in moderate-to-severe eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small-molecule treatments for developmental and epileptic encephalopathies, other epilepsies, neuropathic pain, and tinnitus. Please visit www.knoppbio.com.
ABOUT DEXPRAMIPEXOLE
Dexpramipexole, a selective inhibitor of eosinophil maturation, is an oral small molecule drug in development by Knopp for asthma and other eosinophil-associated diseases. In hypereosinophilic syndrome, dexpramipexole has previously been shown in a Phase 2 trial to significantly reduce requirements for oral corticosteroids and in a subset of patients to produce durable disease remission. In its earlier development in amyotrophic lateral sclerosis, dexpramipexole was shown to be well tolerated in Phase 1, Phase 2, and Phase 3 trials comprising approximately 1,200 patients.
This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events, or otherwise.
Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing pre-clinical or clinical study to verify their safety and effectiveness.
Media inquiries:
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005183/en/
Contact information
Tom Petzinger
tom@knoppbio.com
412-488-1776
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TVS Motor Company Appoints Marcel Driessen as Division Head – Europe to Drive Next Phase of Growth25.8.2026 13:49:00 EEST | Press release
TVS Motor Company (TVSM), part of TVS VENU, and a reputed global manufacturer of two and three-wheelers, today announced the appointment of Marcel Driessen as Division Head – Europe, effective September 15th, 2026 to strengthen its international business operations and accelerate growth across key global markets. Marcel will spearhead the next phase of expansion for both the brands TVSM and Norton Motorcycles in one of the company's most strategically important regions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260825464349/en/ Marcel Driessen, Division Head – Europe, TVS Motor Company Marcel joins TVS Motor Company with more than three decades of international leadership experience across the automotive and premium motorcycle industries. Throughout his distinguished career, he has held senior commercial and management positions with some of the world's most respected brands, including Yamaha, BMW Motorrad, Ducati, Piag
NIQ and The OpenAI Deployment Company Collaborate to Bring Consumer Intelligence into Enterprise Workflows25.8.2026 13:45:00 EEST | Press release
NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced a collaboration with The OpenAI Deployment Company (“DeployCo”) to further extend its AI suite of products in the NIQ Optiq Suite, including NIQ Optiq Chat, Optiq Mobile, and Optiq Bridge. The collaboration builds on the AI-native growth and product momentum NIQ reported in its Q2 results and will help NIQ extend and deliver its proprietary intelligence directly into the enterprise systems and workflows clients use every day. AI is rearchitecting decision-making across commerce, reshaping how companies analyze markets, make decisions and execute work. But model capabilities alone are not enough. Business outcomes depend on the quality of the data, harmonization, semantic context and domain intelligence behind those systems. Through its work with DeployCo, NIQ is advancing how AI-ready intelligence can be accessed, applied and embedded across enterprise workflows. “We expect this work to help us build faster
SCP Standard Capital Partners AG Completes Its Strategic Shift Towards Defence Technology Through the Acquisition of Vanea Technologies GmbH and Nocturne Technologies GmbH – Plans to Change Its Name to VANEA AG25.8.2026 13:26:00 EEST | Press release
SCP Standard Capital Partners AG (“SCP” or the “Company”) has today agreed to acquire all shares in Vanea Technologies GmbH (“VANEA”) and Nocturne Technologies GmbH (“Nocturne”). The shares will be acquired by way of capital increases in kind, utilising the Authorised Capital 2026, in return for the issue of new shares and cash compensation. VANEA is a young technology company specialising in the development of defence solutions for the dawning era of autonomous warfare. Nocturne, based in Osnabrück – also known as Nocturne Defence – specialises in forward-looking solutions in the field of civil and military counter-UAS systems (drone defence). The purchase price for the acquisition of VANEA is in the low six-figure range and comprises a cash component and a share component. The purchase price for the acquisition of Nocturne comprises a cash component and a share component, which together amount to a figure in the high six-figure range. Going forward, the Company will focus on developi
INSEAD Marks the First Milestone in Its Europe Campus Re-imagination25.8.2026 13:07:00 EEST | Press release
INSEAD, The Business School for the World, yesterday inaugurated the Tour Desmarais, marking a major milestone in its Europe Campus Re-imagination (ECR)—a ten-year, €350 million investment totransform its campus in Fontainebleau for the future of business education and learning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260825752920/en/ From left: Charles Desmarais, Maria Desmarais, Nicolas Desmarais, Paul Desmarais MBA'79, Helene Desmarais, Jean-Michel Wilmotte, Francisco Veloso, Paul Desmarais III MBA'10J, Borina Andrieu The inauguration took place in the presence of members of the Desmarais family, public officials, members of the INSEAD community, partners and distinguished guests from across the business, academic and philanthropic communities. Nestled within one of Europe's most iconic forests, the INSEAD Europe Campus has welcomed students, executives, researchers and entrepreneurs from around the world for more
CTC Global Expands Advanced Conductor Portfolio with ACCC® Plus Conductor25.8.2026 13:00:00 EEST | Press release
CTC Global, the world’s leading developer and manufacturer of high-capacity Advanced Conductors, today announced the introduction of the ACCC® Plus Conductor, an enhanced addition to the ACCC® Conductor family. Utilities are facing a new set of transmission planning challenges, as load growth, generation shifts, interconnection queues, permitting constraints, and evolving reliability requirements put increasing pressure on both existing and new transmission infrastructure. Utilities must quickly add capacity while managing project costs, clearance constraints, structure requirements, and long-term performance. Built on highly proven ACCC® Conductor Technology, the ACCC® Plus Conductor is designed to deliver greater mechanical performance, improved efficiency, and enhanced sag performance, while offering greater design flexibility for demanding transmission line applications. The new conductor option features a higher-strength, higher-modulus core than standard ACCC® Conductor, supporti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom